Bio Green Med Solution, Inc. Earnings Per Share Disclosure
15. Net Loss Per Share
Basic and diluted net loss per share attributable to common stockholders was calculated as follows:
Years ended December 31, | ||||||
2024 | 2023 | |||||
Numerator: | ||||||
Net loss | $ | (11,212) | $ | (22,555) | ||
Dividend on convertible exchangeable preferred shares | — | (201) | ||||
Net loss attributable to common shareholders | $ | (11,212) | $ | (22,756) | ||
Denominator: | ||||||
Weighted-average number of common shares used in loss per share – basic and diluted | 5,355,379 | 850,815 | ||||
Loss per share - basic and diluted | $ | (2.09) | $ | (26.75) | ||
Potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
| December 31, | December 31, | ||
| 2024 |
| 2023 | |
Stock options |
| 118,489 |
| 142,796 |
Restricted Stock Units |
| 39,414 |
| 34,498 |
6% convertible exchangeable preferred stock |
| 3 |
| 6 |
Series A preferred stock |
| 440 |
| 440 |
Series B preferred stock |
| — |
| 39,667 |
Common stock warrants |
| 28,123,778 |
| 635,550 |
Total shares excluded from calculation |
| 28,282,124 |
| 852,957 |
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2024 | Apr 2, 2025 | Showing above |
| 2020 | Mar 1, 2021 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.